Objective: The aim of this study is to comprehensively evaluate the safety and efficacy of the 20-kDa linear (Pegylated Interferon) PEGIFN alpha-2a and Ribavirin combination versus Sofosbuvir, 20-kDa linear PEGIFN alpha-2a and Ribavirin combination in treatment of chronic hepatitis C (CHC) Egyptian patients as well as studying variables that affect the response to this treatment. Methods: A total of 202 adult Egyptian patients divided into 2 groups; IR group composed of 97 patients enrolled to receive PEG-IFN and RBV combination treatment, and IRS group composed of 105 patients enrolled to receive PEG-IFN, RBV, and sofosbuvir combination. Results: In IR group 62 (63.92%) had end of treatment response (ETR), of the 62 patients with ETR, 11(11.34%) had a relapse while 51 (52.58%) patients achieved sustained virological response (SVR). In IRS group six (5.72%) patients were non-responders, where as 99 (94.28%) patients attained ETR of whom 29 (27.62%) had a relapse while 70 (66.67%) patients achieved SVR. Conclusion: This new combination containing sofosbuvir is still ineffective enough so that more researches and treatment combination needed to combat hepatitis C epidemic in Egypt at reasonable cost.
INTRODUCTION
Hepatitis C virus (HCV) infection is the principal cause of chronic liver disease, Hepatocellular carcinoma (HCC) and the leading indication for liver transplantation. 1 Nearly 150 million people worldwide are currently infected with the HCV 2 and approximately 3.2 to 5.2 million of these individuals are in the United States 3, 4 . In Egypt, the situation is quite worse. The national prevalence rate of HCV antibody positivity estimated at 14.7% of the country's population 5, 6 , with an estimated 91% of infections are caused by genotype 4. [7] [8] [9] So, Egypt has the highest HCV seroprevalence in the world. [10] [11] [12] Today, HCV infection and its complications are among the leading public health challenges in Egypt. 13 Previously, the most effective therapy available for chronic hepatitis C (CHC) was subcutaneous injection of interferon (IFN) alpha combined with oral ribavirin (RBV). 14, 15 Both IFN alpha2a and IFN alpha-2b have a serum half-life of >12 hours. Thus, thrice-weekly subcutaneous injections are required to maintain effective drug concentrations for the treatment of CHC. 16, 17 However, a majority of patients fail to clear the virus i.e., achieve a sustained virological response (SVR) with this treatment. 18, 19 Conjugation of polyethylene glycol (PEG) to several biologic responsemodifying proteins has been shown to increase the proteins' serum half-life, reduce their sensitivity to proteolysis, and reduce antigenicity. 20, 21 Coadministration of PEGIFN alpha-2a and RBV has been shown to further improve the anti-HCV activity of IFN. 22 Sofosbuvir is a uridine nucleotide analog, with specific inhibition of HCV NS5B RNA-dependent RNA polymerase (RdRp) activity. Sofosbuvir remains largely intact in transit through the gastrointestinal system and is efficiently taken up by hepatocytes. 23 Through sequential hydrolysis by hepatic serine protease cathepsin A (CatA) and serine esterase carboxyl esterase 1 (CES1), the active form (GS-566500) is created. This compound is further hydrolyzed by histidine followed by two additional phosphorylations through the pyrimidine biosynthesis pathway to create the pharmacologically active nucleoside analog triphosphate (GS-461203). 24 The NEUTRINO study 25 was a single-group, open label study of treatment-naive patients with hepatitis C genotype 1, 4, 5, and 6, treated with SOF plus PEG and RBV for 12 weeks. The study population of 327 included 17% patients of African descent and 17% with cirrhosis. Ninety percent of patients in this analysis attained sustained viral response.
MATERIALS AND METHODS

Patient Selection
Patients were screened and entered the study if they: were aged 18-65 years old, had at least one elevated serum alanine aminotransferase (ALT) level more than twice the upper limit of normal during the 6 months before treatment, had positive serum anti-HCV antibodies, had a detectable HCV-RNA on testing with polymerase chain reaction (PCR), and agreed to sign an informed consent to participate in the study.
Patients were excluded from the study if they don't meet the above mentioned inclusion criteria, had other causes of chronic liver disease (hepatitis B 
Monitoring
Patients were carefully monitored every week by physical examination with stress on treatment induced adverse effects together with laboratory parameters evaluations that included: complete blood picture (CBC), 
Virologic Assessment and Definition of Virologic Response
HCV-RNA was quantified by Amplicor Monitor Assay; Roch Molecular Systems. The specimen requirement for HCV-RNA by PCR is one EDTA Serum needs to be separated from cells within 6 hours of collection and refrigerated or frozen to avoid degradation of viral RNA. A DNA copy of viral RNA is synthesized by reverse transcription. This DNA molecule is amplified millions of times by PCR. The lower limit of detection for the assay was 0.6 KIU/ml.
For IR group the end of treatment response (ETR) as undetectable HCV-RNA at the end of the 48-week course of treatment; and sustained virological response (SVR) as undetectable HCV-RNA 24weeks after finishing treatment. For IRS group ETR defined as undetectable HCV-RNA at the end of the 12-week course of treatment; and SVR defined as undetectable HCV-RNA 12 weeks after finishing treatment. Patients had a detectable HCV RNA at any time after the ETR, had no viral load testing after the ETR and a detectable HCV-RNA on their last HCV viral load test while on treatment or died were considered non-responders and had to discontinue treatment according to hospital protocol. This was also done with patients who showed reappearance of HCV-RNA while on treatment (breakthrough response). Relapse is defined as reappearance of HCV-RNA after finishing the course of treatment. Anti-viral efficacy was evaluated for all study patients using intention-to-treat analysis (ITT analysis).
Statistical Analysis
Results are presented as means ± standard deviations (SD) for continuous variables, median and range for non-normally distributed variables, and as frequencies and percentages for categorical data.
Analysis of normality was performed using the Kolmogorov-Smirnov test. Categorical data and proportions were analyzed using the χ2 test or the Fisher's exact test, as required. Student's t test was used to compare the means of the 2 groups with normal distributions, and the Mann-Whitney U test was used to compare variables with non-normal distributions.
All tests were 2-tailed. P-values <0.05 were considered statistically significant. Analysis was conducted using SPSS version 22.
RESULTS
A total of 202 adult Egyptian patients were selected from those patients who were enrolled for treatment of HCV at Ahmed Maher Teaching Hospital, divided into 2 groups; IR group composed of 97 patients enrolled to receive PEG-IFN and RBV combination, and IRS group composed of 105 patients enrolled to receive PEG-IFN, RBV, and Sofosbuvir combination. 
Baseline Characteristics
The population in IR group studied comprised 79 (81.45%) males and 18 (18.55%) females; age ranged between 24 -62 years with a mean age of 48.51 ± 8.01 years ( Figure 1 shows the distribution of patients' age among different groups); also, weight ranged from 44 -118 kg with a mean weight of 69.4 ± 12.23 kg. The population in IRs group studied comprised 62 (59.04%) males and 43 (40.95%) females; age ranged between 35-62 years with a mean age of 49 ± 7.26 years ( Figure 1 shows the distribution of patients' age among different groups); also, weight ranged from 40-100 kg with a mean weight of 73.97 ± 11.39 kg. Table 1 summarizes the   baseline demographic and table 2 summarizes the clinical data for the studied population of both groups.
Adverse Events (AEs)
In IR group all patients had at least one AE during treatment. Most treatment-related AEs were considered mild or moderate in severity and were consistent with flu-like symptoms such as fever, headache, and fatigue. All AEs reported are summarized in (Table 3) . In IRS group patients suffer from same symptoms as in IR group but headache and fatigue more predominant in IRS group as summarized in (Table 3) . 
Clinical Laboratory Evaluation
In IR group most changes in laboratory values were classified by WHO criteria. 26 Table 4 summarizes laboratory abnormalities encountered during treatment. Grade 3 (500 to <750/mm 3 ) and grade 4 (<500/mm 3 ) neutropenia occurred in 3 (3.1%) and 2 (2.1%) patients, respectively. One of the patients with grade 4 neutropenia discontinued treatment at week 32 (ANC 345/mm3) but achieved an SVR, and the other had improved counts when re-tested and was managed with suspending PEGIFN alpha-2a doses for 2 weeks. Grade 2 thrombocytopenia (PLT 50,000 -75,000/mm 3 ) occurred in 10 patients (10.3%), and only one patient (1.03%) had grade 3 (49,000/mm 3 ) that was managed by PEG IFN alpha-2a dose reduction. The magnitude of reductions in hemoglobin (Hb) concentration from baseline was similar in all age groups. At nadir, the mean change from baseline was -4.21 ± 1.55 g/dl. Anemia was managed through dose reduction of RBV in 47 (48.45%) patients and 12 patients (12.37%) required both PEGIFN alpha-2a and RBV dose reduction.
Figure 1. Distribution of patients' age among different groups
In IRS group, at nadir, the mean change from baseline of Hb is -3.45 ± 1.91 g/dl. Anemia was managed through dose reduction of RBV in 20 (19.05%) patients and one patient (0.95%) requires PEGIFN alpha-2a reduction. (Table 5 ) summarize Adverse events leading to dose reduction or interruption in both groups.
Virological Response
In IR group Twenty-two (22.68%) patients were non-responders, whereas 75 (77.32%) patients attained early virological response (EVR) of whom 62 (63.92%) had ETR and 13 (13.4%) had a breakthrough response. Of the 62 patients with ETR, 11 (11.34%) had a relapse while 51 (52.58%) patients achieved SVR.
In IRS group six (5.72%) patients were nonresponders, where as 99 (94.28%) patients attained ETR of whom 29 (27.62%) had a relapse while 70 (66.67%) patients achieved SVR; Figure 2 summarizes patient response according to treatment.
Factors associated with SVR were assessed using variables in 
DISCUSSION
Here, we present a "real-world data" cohort of patients who were treated for chronic HCV4 infection with 12 weeks treatment of SOF/IFN/RBV (IRS group) compared to cohort of patients treated with old standard IFN/RBV (IR group) for 48 weeks. There are a few head to head comparisons such our study in literature. Realworld data about the safety and efficacy of SOF/IFN/RBV combination in HCV genotype 4 are limited. In the registration trial (NEUTRINO trial) by 25 . Only 28 treatment-naïve patients with HCV genotype 4 infections were enrolled. The SVR frequency among this subgroup was 96.4% which is obviously greater than our reported frequency of 66.67%, also our study largely differs from result of Wehmeyer et al 27 , which report that patients receiving SOF/IFN/RBV achieve 100% SVR which reflects that data obtained from clinical trials are not always reproducible in real clinical settings. Most important explanation of difference in result between our study (IRS group) and studies of both Lawitz et al and Wehmeyer et al that we study on large number of patient (N=105), on other hand they study on 28, 24 respectively. The IR group analysis revealed that SVR 52.58% so treatment of patients with old standard IFN/RBV treatment at increased risk for a virological failure than IRS group, one of important factor that may significantly affect response of IFN/RBV in IR group is adherence because of longer duration (48 weeks) of therapy. It is also found that the SVR rate decreases significantly with increasing age and Metavir fibrosis score in both groups. This indicates that higher SVR rates are expected in younger adults with low Metavir fibrosis score (0-2) than older patients with more advanced fibrosis and starting therapy for aged patient with advanced fibrosis may not be preferred to decrease costs and unnecessary drug exposure and adverse effects. Several studies reported that SVR rate varies significantly by sex. [28] [29] [30] [31] [32] However, the effect of sex was non-significant in our study. An interesting finding in IR group study is that patients received lower doses of RBV or RBV/IFN due to AEs had an unexpected significantly higher SVR rate than those who received full doses. This finding may be due to higher plasma RBV level in some patients that led to more AEs necessitating dose reduction. But in IRS group patients who required RBV and RBV/IFN dose reduction due to AEs had a non-significant SVR rate than those than those who received full dose of RBV and IFN because of shorter duration of therapy in IRS group than IR group.
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